1. Synthesis, design, and optimization of a potent and selective series of pyridylpiperazines as promising antimalarial agents.
- Author
-
da Silva Oliveira DD, Paz F, Brito NPF, Krüger A, Martinho ACC, Lapierre TJWJD, de Oliveira Souza F, Maltarollo VG, Kronenberger T, Mendes MS, Nonato MC, Pilau EJ, Wrenger C, Wunderlich G, and Rezende Júnior CO
- Subjects
- Structure-Activity Relationship, Humans, Molecular Structure, Dose-Response Relationship, Drug, Animals, Antimalarials pharmacology, Antimalarials chemical synthesis, Antimalarials chemistry, Plasmodium falciparum drug effects, Piperazines chemistry, Piperazines pharmacology, Piperazines chemical synthesis, Drug Design, Parasitic Sensitivity Tests
- Abstract
An optimization of the pyridylpiperazine series against Plasmodium falciparum has been performed, exploring a structure-activity relationship carried out on the toluyl fragment of hit 1, a compound with low micromolar activity against Plasmodium falciparum discovered by high-throughput screening. After confirming the crucial role played by this aryl fragment in the antiplasmodial activity, the replacement of the ortho-methyl substituent of 1 by halogenated ones led to an improvement for four analogs, either in terms of potency, expected pharmacokinetics profile, or both. Further introduction of endocyclic nitrogens in this fragment identified two more optimized compounds, 20 and 23, which are expected to be much more metabolically stable than 1. Additional assessment of the cytotoxicity, Ligand Lipophilic Efficiency, potency against the chloroquine-resistant Dd2 strain and in silico ADMET predictions revealed a satisfactory profile for most compounds, ultimately identifying the four optimized compounds 7, 9, 20 and 23 as promising compounds for further lead optimization of this series against Plasmodium falciparum., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF